Orn8, Urotensin II, human
CAS No. 479065-85-5
Orn8, Urotensin II, human( ——— )
Catalog No. M41748 CAS No. 479065-85-5
[Orn8]-Urotensin II (human), a peptide analog of urotensin II, is a UT receptor agonist. [Orn8]-Urotensin II (human) increases intracellular calcium levels in HEK293.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 978 | Get Quote |
|
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameOrn8, Urotensin II, human
-
NoteResearch use only, not for human use.
-
Brief Description[Orn8]-Urotensin II (human), a peptide analog of urotensin II, is a UT receptor agonist. [Orn8]-Urotensin II (human) increases intracellular calcium levels in HEK293.
-
Description[Orn8]-Urotensin II (human), a peptide analog of urotensin II, is a UT receptor agonist. [Orn8]-Urotensin II (human) increases intracellular calcium levels in HEK293.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number479065-85-5
-
Formula Weight1374.55
-
Molecular FormulaC63H83N13O18S2
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Camarda V, et al. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol. 2004 Sep 13;498(1-3):83-6.?
molnova catalog
related products
-
ERAP1-IN-1
ERAP1-IN-1 is an endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitor. ERAP1-IN-1 competitively inhibits ERAP1 activity towards a nonamer peptide representative of physiological substrates.
-
β-Defensin-4, human
β-Defensin-4, human
-
VULM 1457
VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes.
Cart
sales@molnova.com